1. Home
  2. OZ vs KZIA Comparison

OZ vs KZIA Comparison

Compare OZ & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Belpointe PREP LLC Units

OZ

Belpointe PREP LLC Units

N/A

Current Price

$36.65

Market Cap

194.7M

Sector

N/A

ML Signal

N/A

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

BUY

Current Price

$7.85

Market Cap

186.7M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
OZ
KZIA
Founded
2020
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
194.7M
186.7M
IPO Year
2020
2002

Fundamental Metrics

Financial Performance
Metric
OZ
KZIA
Price
$36.65
$7.85
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $28.33
AVG Volume (30 Days)
27.7K
★ 229.9K
Earning Date
11-13-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $9,187,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 243.44
N/A
52 Week Low
$35.42
$4.86
52 Week High
$69.00
$17.40

Technical Indicators

Market Signals
Indicator
OZ
KZIA
Relative Strength Index (RSI) 26.43 37.13
Support Level $35.42 $6.72
Resistance Level $48.00 $8.18
Average True Range (ATR) 1.40 0.68
MACD 0.02 0.09
Stochastic Oscillator 13.78 40.26

Price Performance

Historical Comparison
OZ
KZIA

About OZ Belpointe PREP LLC Units

Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset. The majority of the revenue is earn from mixed-use segment.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: